133 related articles for article (PubMed ID: 34967032)
1. Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory myopathies is dependent on target protein properties.
Ichimura Y; Konishi R; Shobo M; Inoue S; Okune M; Maeda A; Tanaka R; Kubota N; Matsumoto I; Ishii A; Tamaoka A; Shimbo A; Mori M; Morio T; Kishi T; Miyamae T; Tanboon J; Inoue M; Nishino I; Fujimoto M; Nomura T; Okiyama N
J Dermatol; 2022 Apr; 49(4):441-447. PubMed ID: 34967032
[TBL] [Abstract][Full Text] [Related]
2. An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.
Fredi M; Cavazzana I; Ceribelli A; Cavagna L; Barsotti S; Bartoloni E; Benucci M; De Stefano L; Doria A; Emmi G; Fabris M; Fornaro M; Furini F; Giudizi MG; Govoni M; Ghirardello A; Iaccarino L; Iannone F; Infantino M; Isailovic N; Lazzaroni MG; Manfredi M; Mathieu A; Marasco E; Migliorini P; Montecucco C; Palterer B; Parronchi P; Piga M; Pratesi F; Riccieri V; Selmi C; Tampoia M; Tripoli A; Zanframundo G; Radice A; Gerli R; Franceschini F;
Clin Rev Allergy Immunol; 2022 Oct; 63(2):240-250. PubMed ID: 35092577
[TBL] [Abstract][Full Text] [Related]
3. Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera.
Cavazzana I; Fredi M; Ceribelli A; Mordenti C; Ferrari F; Carabellese N; Tincani A; Satoh M; Franceschini F
J Immunol Methods; 2016 Jun; 433():1-5. PubMed ID: 26906088
[TBL] [Abstract][Full Text] [Related]
4. Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies.
Hamaguchi Y; Kuwana M; Takehara K
Clin Rheumatol; 2020 Nov; 39(11):3489-3497. PubMed ID: 32385758
[TBL] [Abstract][Full Text] [Related]
5. Analytic and Clinical Validity of Myositis-Specific Antibodies by Line-Blot Immunoassay Is Essential.
Tseng CW; Satoh M; Hasegawa T; Tanaka S; Chen YM
J Clin Rheumatol; 2024 Jan; 30(1):e23-e28. PubMed ID: 37983669
[TBL] [Abstract][Full Text] [Related]
6. Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash.
Ichimura Y; Konishi R; Shobo M; Inoue S; Okune M; Maeda A; Tanaka R; Kubota N; Matsumoto I; Ishii A; Tamaoka A; Shimbo A; Mori M; Morio T; Kishi T; Miyamae T; Tanboon J; Inoue M; Nishino I; Fujimoto M; Nomura T; Okiyama N
Rheumatology (Oxford); 2022 Mar; 61(3):1222-1227. PubMed ID: 34152410
[TBL] [Abstract][Full Text] [Related]
7. Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.
Li L; Liu C; Cheng L; Yan S; Chen H; Li Y
Clin Rheumatol; 2021 Mar; 40(3):819-832. PubMed ID: 32681367
[TBL] [Abstract][Full Text] [Related]
8. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
9. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study.
Yamasaki Y; Kobayashi N; Akioka S; Yamazaki K; Takezaki S; Nakaseko H; Ohara A; Nishimura K; Nishida Y; Sato S; Kishi T; Hashimoto M; Mori M; Okazaki Y; Kuwana M; Ohta A
Rheumatology (Oxford); 2021 Oct; 60(10):4821-4831. PubMed ID: 33576399
[TBL] [Abstract][Full Text] [Related]
11. The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies.
Xu Q; Li QX; Bi FF; Duan HQ; Luo YB; Yang H
Clin Rheumatol; 2021 Feb; 40(2):613-624. PubMed ID: 32671659
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies.
Cavazzana I; Richards M; Bentow C; Seaman A; Fredi M; Giudizi MG; Palterer B; Pratesi F; Migliorini P; Franceschini F; Satoh M; Ceribelli A; Mahler M
J Immunol Methods; 2019 Nov; 474():112661. PubMed ID: 31442464
[TBL] [Abstract][Full Text] [Related]
13. Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts.
Zhong L; Yu Z; Song H
Clin Immunol; 2019 Jan; 198():11-18. PubMed ID: 30445156
[TBL] [Abstract][Full Text] [Related]
14. Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody.
Yan TT; Zhang X; Yang HH; Sun WJ; Liu L; Du Y; Xue J
Clin Rheumatol; 2021 Sep; 40(9):3695-3702. PubMed ID: 33712891
[TBL] [Abstract][Full Text] [Related]
15. A New Immunodot Assay for Multiplex Detection of Autoantibodies in a Cohort of Italian Patients With Idiopathic Inflammatory Myopathies.
Tampoia M; Notarnicola A; Abbracciavento L; Fontana A; Giannini M; Louis Humbel R; Iannone F
J Clin Lab Anal; 2016 Nov; 30(6):859-866. PubMed ID: 27074881
[TBL] [Abstract][Full Text] [Related]
16. The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population.
Loganathan A; McMorrow F; Lu H; Li D; Mulhearn B; McHugh NJ; Tansley SL
Front Immunol; 2022; 13():975939. PubMed ID: 36177007
[TBL] [Abstract][Full Text] [Related]
17. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
[TBL] [Abstract][Full Text] [Related]
18. Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series.
Bermudez J; Heim X; Bertin D; Coulon B; Puech B; Bardin N; Reynaud-Gaubert M
Expert Rev Respir Med; 2020 Aug; 14(8):845-850. PubMed ID: 32394768
[TBL] [Abstract][Full Text] [Related]
19. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies.
Wong VT; So H; Lam TT; Yip RM
Acta Neurol Scand; 2021 Feb; 143(2):131-139. PubMed ID: 32762037
[TBL] [Abstract][Full Text] [Related]
20. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.
Ueki M; Kobayashi I; Takezaki S; Tozawa Y; Okura Y; Yamada M; Kuwana M; Ariga T
Mod Rheumatol; 2019 Mar; 29(2):351-356. PubMed ID: 29532710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
